rector – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail:
lfischer@keryx.com Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):Three Months Ended December 31, Year Ended December 31,2011201020112010REVENUE:License revenue
$
--
$
--
$
5,000
$
--OPERATING EXPENSES:Research and development:Non-cash compensation
187
238
803
1,236Other research and development
6,676
4,144
26,209
13,728Total research and development
6,863
4,382
27,012
14,964General and administrative:Non-cash compensation
341
278
1,289
1,237Other general and administrative
1,497
1,341
5,448
5,014Total general and administrative
1,838
1,619
6,737
6,251TOTAL OPERATING EXPENSES8,701
6,001
33,749
21,215OPERATING LOSS(8,701)
(6,001)
(28,749)
(21,215)OTHER INCOME: Interest and other income, net
80
567
380
764LOSS FROM CONTINUING OPERATIONS(8,621)
(5,434)
(28,369)
(20,451)Gain from discontinued operations
246
120
246
120NET LOSS$
(8,375)
$ (5,314)
$ (28,123)
$ (20,331)NET LOSS PER COMMON SHAREContinuing operations
$
(0.12)
$
(0.09)
$
(0.42)
$
(0.34)Discontinued operations--* --* --* --* Basic and diluted net loss per common share
$
(0.12)
$
(0.09)
$
(0.42)
$
(0.34)SHARES USED IN COMPUTING NET LOSS PER COMMON SHAREBasic
71,022,951
61,266,886
67,370,354
58,987,854Diluted
71,022,951
61,266,886
67,370,354<
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results2.
Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting3.
Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting4.
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference5.
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results6.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results7.
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations8.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results9.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results10.
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering11.
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical